Invasive Aspergillosis
Rituximab does NOT significantly predispose patients to invasive aspergillosis, making this the correct answer (D).
Infection Risk Profile with Rituximab
Rituximab, an anti-CD20 monoclonal antibody, causes profound B-cell depletion lasting up to 6 months or longer 1, 2. This creates a specific pattern of infectious vulnerability that primarily affects encapsulated bacteria and certain viral pathogens, but notably spares typical opportunistic fungal infections like invasive aspergillosis.
Infections That ARE Increased by Rituximab:
Encapsulated Bacterial Infections (Options A, C, E):
- Pneumococcal pneumonia - Rituximab significantly impairs antibody responses to pneumococcal antigens, with studies showing reduced vaccine immunogenicity in rituximab-treated patients 3, 2
- Meningococcal meningitis - The B-cell depletion compromises humoral immunity against Neisseria meningitidis
- Haemophilus influenzae infections - Similar mechanism as other encapsulated organisms; impaired opsonization and clearance
The evidence consistently documents that rituximab increases risk for "atypical bacterial infection" and specifically mentions upper respiratory tract infections as common complications 4, 5. The FDA label explicitly notes upper respiratory tract infections, urinary tract infections, bronchitis, and sinusitis as frequent infectious complications 6.
Hepatitis B Reactivation (Option B):
- Definitively increased risk - Multiple guidelines mandate screening for hepatitis B before rituximab initiation 7
- Reactivation can be fatal and is a well-established complication
- Prophylaxis is standard of care in HBV-positive patients receiving rituximab
Viral Infections:
- Progressive multifocal leukoencephalopathy (JC virus) 7
- Cytomegalovirus reactivation 5, 8
- Severe arboviral neuroinvasive disease with 79% mortality in one series 9
- Herpes simplex and herpes zoster 6
Why NOT Invasive Aspergillosis:
Mechanistic Explanation: Invasive aspergillosis requires profound T-cell and neutrophil dysfunction, not B-cell depletion. The pathogenesis involves:
- Impaired neutrophil-mediated killing of Aspergillus conidia
- Defective T-cell responses (particularly Th1/Th17)
- Prolonged severe neutropenia
Clinical Evidence:
- None of the guideline documents [5-2] list aspergillosis as a rituximab-associated infection
- The FDA label 6 does not mention fungal infections beyond Pneumocystis jirovecii pneumonia
- Studies in Waldenström's macroglobulinemia patients treated with rituximab report "pneumonitis/pneumonia" but not invasive aspergillosis 5
- The lung transplant monitoring guideline 4 mentions Pneumocystis prophylaxis but not anti-mold prophylaxis for rituximab
Contrast with Other Agents: Alemtuzumab (anti-CD52), which depletes both B and T cells, shows "high incidence of grade ≥3 cytopenias, cytomegalovirus reactivation" 5 but even this more profoundly immunosuppressive agent doesn't prominently feature aspergillosis in safety profiles.
Clinical Implications:
Prophylaxis Recommendations:
- Pneumocystis jirovecii pneumonia prophylaxis should be considered 4
- Hepatitis B screening mandatory before treatment 7
- Vaccination timing: avoid within 6 months post-rituximab; consider booster doses and antibody titer monitoring 2
- No routine anti-mold prophylaxis needed for rituximab monotherapy
Common Pitfall: Clinicians may conflate the immunosuppression from rituximab with that from combination chemotherapy regimens. When rituximab is combined with agents like cyclophosphamide or bendamustine, the infection profile changes dramatically due to neutropenia from the chemotherapy component 5. Rituximab monotherapy does not cause the profound neutropenia required for invasive aspergillosis.